KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Assets: 2010-2024

Historic Assets for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $1.6 billion.

  • Pacira BioSciences' Assets fell 14.73% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 14.73%. This contributed to the annual value of $1.6 billion for FY2024, which is 1.33% down from last year.
  • Per Pacira BioSciences' latest filing, its Assets stood at $1.6 billion for FY2024, which was down 1.33% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Assets ranged from a high of $2.1 billion in FY2021 and a low of $1.3 billion during FY2020.
  • Over the past 3 years, Pacira BioSciences' median Assets value was $1.6 billion (recorded in 2023), while the average stood at $1.6 billion.
  • Its Assets has fluctuated over the past 5 years, first spiked by 62.83% in 2021, then dropped by 18.99% in 2022.
  • Pacira BioSciences' Assets (Yearly) stood at $1.3 billion in 2020, then surged by 62.83% to $2.1 billion in 2021, then fell by 18.99% to $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then declined by 1.33% to $1.6 billion in 2024.